Pharma firms valuations do not factor in threats from acceleration in generics adoption in India ...Middle East

New Delhi:  The current implied domestic valuations of pharma companies do not adequately factor in threats from any acceleration in the pace of adoption of unbranded and trade generics in India, as per a report by Kotak Institutional Equities. In another instance exemplifying the Indian government’s intent to push generics, it has set an imposing timeline to achieve its objective of reaching 25,000 Jan Aushadhi stores. The government targets to increase the store count by 2.5X to 25,000 in less than 2.5 years (end-FY2026), the report said. Apart from store additions, there is also an effort to improve the geospatial coverage of stores (skewed toward South India currently). On the other han

Hence then, the article about pharma firms valuations do not factor in threats from acceleration in generics adoption in india was published today ( Monday 18/12/2023 - 11:08 AM ) and is available on News room odisha ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Pharma firms valuations do not factor in threats from acceleration in generics adoption in India )

Also on site :

• Sam’s Club is Selling a Giant Bag of Lucky Charms Marshmallows For Just $9–and There’s a Magical Surprise Inside
• ‘I Will Find You’ Review: Sam Worthington and Britt Lower Lead Netflix’s Wheel-Spinning, Pulpy Harlan Coben Thriller
• Target’s ‘Stylish’ Accent Chair With a Built-In Pet Nook Is 53% Off Ahead of Circle Deal Days